The Akt gene is the cellular homolog of the v-akt oncogene transduced by AKT8, an acute transforming retrovirus in mice that was originally described in 1977 (Staal et al., 1977) . In 1991, three independent research groups cloned and characterized Akt kinases. Philip Tsichlis' group identified v-akt as the gene transduced by the rodent retrovirus AKT8 (Bellacosa et al., 1991) , and subsequently showed that its cellular homolog, then named c-akt, encoded the cytoplasmic serine-threonine protein kinase Akt in mice (Bellacosa et al., 1993) . Also in 1991, two research groups in England and Switzerland identified Akt when searching for novel kinases related to protein kinases A and C (PKA/PKC) (Coffer and Woodgett, 1991; Jones et al., 1991b) . Thus, Akt is also frequently referred to as protein kinase B (PKB).
All Akt isoforms share similar structures, namely an N-terminal regulatory domain including a pleckstrin homology (PH) domain; a hinge region connecting the PH domain to a kinase domain with serine/threonine specificity; and a C-terminal region necessary for the induction and maintenance of its kinase activity (for review, see Chan et al., 1999) . Mammalian cells express three closely related Akt isoforms: Akt1 (PKBa), Akt2 (PKBb) and Akt3 (PKBg), all encoded by different genes. Akt1 is ubiquitously expressed at high levels (Coffer and Woodgett, 1991; Jones et al., 1991b; Bellacosa et al., 1993) . In contrast, Akt2 is highly expressed in insulin-sensitive tissues including the liver, skeletal muscle and adipose tissue (Jones et al., 1991a; Konishi et al., 1994) . The expression of Akt2 is drastically increased during the differentiation of adipose tissue and skeletal muscle (Hill et al., 1999; Vandromme et al., 2001) . Akt3 is expressed most highly in the brain and testis and exhibits lower levels of expression in intestinal organs and muscle tissue (Nakatani et al., 1999a) .
The structural homology between different Akt isoforms extends to their activation mechanism. All Akt isoforms contain PH domains with similar specificities for the D3-phosphorylated phosphoinositide products of phosphatidylinositol 3-kinase (PI3K) . Another similarity is that they are regulated by phosphoinositide-dependent kinase-1 (PDK1), a PH domain-containing kinase downstream of PI3K, which phosphorylates Akt isoforms and other AGC kinase family members on a critical threonine residue in the activation loop (for review, see Toker and Newton, 2000b) .
Several findings point to functional differences between Akt isoforms. These include the observation that overexpression of Akt2, but not Akt1, is sufficient to restore insulin-mediated glucose uptake in Akt2 À/À adipocytes (Bae et al., 2003) ; that glucose uptake in wild-type adipocytes is potently inhibited by siRNA knockdown of Akt2 but not Akt1 ; and that only the expression of human Akt2 and Akt3 is pathologically increased in human cancer, suggesting the involvement of specific Akt isoforms in the onset or propagation of cancer (Cheng et al., 1996; Nakatani et al., 1999b) . Furthermore, although increasing Akt2 activity increases cell motility, invasion and metastatic potential, cells expressing activated Akt1 fail to exhibit this cancer-related phenotype (Arboleda et al., 2003; Hutchinson et al., 2004) . Marked differences regarding the involvement of specific Akt isoforms have also been reported for other human diseases: inherited mutations in AKT2 have been described in familial diabetes (George et al., 2004) ; in contrast, AKT1 coding variations have been associated with familial schizophrenia (Emamian et al., 2004) . Taken together, these findings of varying and isoform-specific involvement in human disease suggest that different Akt isoforms are associated with distinct biological processes.
Phosphatidylinositol 3-kinases: signaling networks upstream of Akt
Critical to the understanding of Akt regulation in cells was the finding that Akt kinase activity is induced following activation of PI3K in growth factor receptormediated signaling cascades (Burgering and Coffer, 1995; Franke et al., 1995; Kohn et al., 1995) . At the plasma membrane, PI3K phosphorylates phosphoinositides on the 3 0 -OH (D3) position of the inositol ring to generate the second messengers phosphatidylinositol-3, 4-bisphosphate (PI-3,4-P 2 ) and phosphatidylinositol-3, 4,5-trisphosphate (PIP 3 ), using phosphatidyinositol-4-phosphate (PI-4-P) and phosphatidylinositol-4,5-bisphosphate (PI-4,5-P 2 ) as substrates, respectively (for review, see Engelman et al., 2006; Hawkins et al., 2006) . Although it had already been demonstrated that the levels of D3-phosphorylated phosphatidylinositols change following growth factor stimulation of cells (Auger et al., 1989) , it was not until 1992 that a cDNA for a kinase capable of phosphorylating phosphatidylinositol (PI) at the D3 position was identified (Hiles et al., 1992) . Subsequently, PI3K was shown to consist of 85 kDa regulatory and 110 kDa catalytic subunits. To date, four catalytic subunits that can phosphorylate PI, PI-4-P and PI-4,5-P 2 in vitro have been cloned (Stephens et al., 1991; Carter et al., 1994) . Class I A PI3Ks (p110a, p110b and p110d) associate with various regulatory subunits to form active heterodimers with distinct expression and activity. These regulatory subunits include: p85a, p55a and p50a, which are all encoded by the pik3r1 gene and have identical C-terminal regions; p85b encoded by pik3r2; and p55g encoded by pik3r3 (for review, see Engelman et al., 2006; Hawkins et al., 2006) .
For Class I A PI3Ks, a simple model for activation by growth factors has been proposed. Upon receptor tyrosine kinase (RTK)-dependent activation, PI3K complexes are recruited to the plasma membrane through the phosphorylation-dependent interaction between Src homology 2 (SH2) domains in their regulatory subunit and the phospho-tyrosine residues on the receptor. As a result, the catalytic subunits are stabilized and brought into proximity of phosphoinositides at the plasma membrane, thus resulting in the subsequent generation of D3-phosphorylated lipid products (for review, see Engelman et al., 2006; Hawkins et al., 2006) . In the case of Class I B PI3K, only one regulatory subunit (p101) has been shown to interact with the p110g catalytic subunit (Stephens et al., 1997) . Class I B PI3K is primarily regulated by small G-proteins such as Ras and by the b/g subunits of G protein-coupled receptors (Lopez-Ilasaca et al., 1997) .
In addition to lipid kinase activity, Class I PI3Ks also exert serine/threonine protein kinase activity against protein substrates. However, the physiological relevance of their protein kinase activity differs significantly between the different members of Class I PI3Ks. More specifically, although only a few examples of Class I A -dependent protein phosphorylation such as the phosphorylation of insulin receptor substrate (IRS)-1 are known (Lam et al., 1994) , the protein kinase activity of Class I B PI3Ks has significant implications for the downstream activation of the mitogen-activated protein kinase cascade (Lopez-Ilasaca et al., 1997) . Other members of the 'extended' family of PI3Ks include class II-type kinases that consist of a single p110-like subunit and prefer PI and PI-4-P as substrates over PI-4,5-P 2 (Virbasius et al., 1996) and class III PI3Ks such as VPS34 that are involved in intracellular vesicle transport and sorting (Schu et al., 1993) . In addition to trafficking vesicles, VPS34 is involved in the regulation of mammalian target of rapamycin (mTOR) activity in response to amino-acid availability (for review, see Nobukuni et al., 2007) , which may be relevant for the autophagic response to nutrient starvation (Kihara et al., 2001; Wurmser and Emr, 2002; Juhasz et al., 2008) .
Oncogenic Aktivation
The original discovery of Akt as the protein encoded by the cellular homolog of the viral oncogene v-akt already implied an important function in cell growth and survival. Numerous studies have since examined oncogenic amplifications of different Akt genes in primary human tumors and cancer cells (for review, see Brazil and Hemmings, 2001; Scheid and Woodgett, 2001 ). Findings of altered AKT2 and AKT3 expression in human cancer support a critical function of the kinases in the disease. The importance of Akt signaling in cancer is further underscored by the discovery of mutations in upstream regulatory molecules including activating somatic mutations in PIK3CA (Bachman et al., 2004; Campbell et al., 2004; Samuels et al., 2004) . The gene for the tumor suppressor phosphatase and tensin homolog (PTEN), a phosphatase that inactivates products of PI3K and inhibits Akt activation (Maehama and Dixon, 1998) , is often mutated in human cancer. Silencing of PTEN is frequently observed in primary tumors and cancer cell lines (for review, see Carnero et al., 2008; Maehama, 2007; Salmena et al., 2008) . Still, these are not the only oncogenic changes leading to increased Akt activity. Alterations of growth factor receptors and Ras also result in Akt hyperactivity in tumor cells (for review, see Shaw and Cantley, 2006) and protect cancer cells against apoptotic insults. Akt hyperactivation is found more frequently in poorly differentiated tumors that are more invasive, grow faster and respond less to treatment. Thus, the pathological finding of hyperactivated Akt in primary tumors is considered to be a negative prognostic marker for disease outcome (for review, see LoPiccolo et al., 2008) . The relevance of altered Akt signaling in primary tumors is further being supported by findings in transgenic mouse models in which expression of activated Akt in the mammary or prostate gland induces pathological changes closely resembling those in human cancers (Hutchinson et al., 2001; White et al., 2001; Majumder et al., 2003) .
It was nearly two decades since the initial description of AKT by Staal (Staal et al., 1977) before polymorphisms and somatic mutations were identified that directly link mutations in Akt isoforms to human cancer. Largescale sequencing efforts have identified germline singlenucleotide polymorphisms and somatic mutations in AKT2 and AKT3 (Sjoblom et al., 2006; Greenman et al., 2007) . Carpten et al. (2007) have described an activating, although rare, mutation in the pleckstrin homology domain of AKT1 in breast, colorectal and ovarial clinical cancer specimens. Others have since confirmed these findings in various cancers (Bleeker et al., 2008; Kim et al., 2008; Malanga et al., 2008) . Specifically, a G>A mutation at nucleotide 49 results in a lysine substitution for glutamic acid at amino acid 17 [AKT1(E17K)] that results in a mutant Akt1 protein with increased plasma membrane recruitment. In culture, cells carrying the mutant allele exhibit a transformed phenotype. Retroviral transduction into E m -Myc transgenic mice induces leukemia similar to myristoylated Akt1 that recapitulates the GAG-Akt fusion protein transduced by AKT8 (Carpten et al., 2007) . Activation of a cytoplasmic kinase by means of a PH domain mutation has previously been reported for Bruton's tyrosine kinase (Btk) (Li et al., 1995) . Still, the identification of such a mutation in Akt is an important confirmation for a direct involvement of Akt in cancer which was previously lacking supporting genetic evidence. Thus, both direct changes in Akt and also indirect changes in modifiers of Akt activity exist that increase pathway strength and drive inherited and somatic tumors in humans (for review, see Brugge et al., 2007) .
These studies strongly validate the search for new treatment approaches that target the Akt pathway. Compounds that inhibit Akt kinase activity are under development; other drugs have been designed that target the regulatory domain of Akt (for review, see LoPiccolo et al., 2008) . Being a protein kinase adds to the value of Akt as a potential drug target, as, historically speaking, loss of function has been easier to achieve through pharmacological targeting than restoration of function. One caveat for targeting Akt, however, is that genetic changes in upstream signaling molecules (for example, PIK3CA) will not only affect Akt signaling, but also other parallel pathways that are regulated by these upstream activators. As such, the observation that the E17K mutation, although not changing the sensitivity of the mutant kinase to ATP-competitive inhibitors, alters its sensitivity to an allosteric kinase inhibitor is very promising (Carpten et al., 2007) . The identification of this mutation provides a defined target for pharmacological therapy with the intrinsic promise of minimizing side effects on normal Akt function in cellular homeostasis.
Akt kinase kinases: PDK1 and PDK2
In addition to phosphoinositide binding, phosphorylation events are required to fully activate Akt. Thus, phosphorylation of threonine residue-308 in its kinase domain (T-loop) and of serine residue-473 within the hydrophobic motif (HM) in the C-terminal tail (according to the mouse Akt1 sequence) potently activate the enzyme and lock it in an active conformation (Alessi et al., 1996a) . The structural analysis of the Akt kinase domain has unraveled the precise nature of the phosphorylation-dependent mechanisms of Akt activation (Yang et al., 2002a (Yang et al., , 2002b . These studies also provide an explanation for the requirement of HM phosphorylation to induce full Akt activity, as phosphorylation at the HM site is required to facilitate a disorder-to-order transition within the structure of the Akt kinase domain and enable the proper alignment of substrates within its active site. In addition to separately solving the structures of both the PH and kinase domain of Akt, advances have been made in understanding the dynamics of the entire polypeptide. Calleja et al. (2007) have used a fluorescent in vivo probe in combination with molecular modeling to examine domain interactions during recruitment and activation of Akt at the plasma membrane. Using this approach, the authors find that Akt is maintained in an inactive state by the interaction of its PH and kinase domains. This conformation is relaxed upon binding of phosphoinositides to the PH domain, thus allowing phosphorylation of Akt by PDK1 and subsequent activation.
Although other kinases, including calmodulin-dependent kinase kinase (CaM-KK), have been proposed to phosphorylate the critical T-loop residues in Akt (Yano et al., 1998) , clear biochemical and genetic evidence has confirmed that in most biological paradigms this activity is conferred by PDK1 Stephens et al., 1998) . PDK1 also contains a PH domain and a serine/ threonine kinase domain. The PH domain in PDK1 is located at its C-terminus and binds to PIP 3 at a higher affinity than the PH domain of Akt . Under physiological conditions, PDK1 is present in the plasma membrane of non-stimulated cells, where it resides as a constitutively activated enzyme. Akt shuttles from the cytoplasm to the plasma membrane only after the levels of D3-phosphoinositides are increased following stimulation of PI3K (Stephens et al., 1998) . Of note, other members of the AGC 'superfamily' of kinases are also phosphorylated by PDK1 on corresponding T-loop motifs, although they may use different mechanisms for colocalization with PDK1 (for review, see Toker and Newton, 2000b) .
The molecular mechanisms governing HM phosphorylation in Akt have remained elusive for a long period. Preliminary experimental data supported both mechanisms involving Akt autophosphorylation (Toker and Newton, 2000a) and phosphorylation by other serine kinases including integrin-linked kinase-1 (ILK1) (Persad et al., 2000) , PDK1 (Balendran et al., 1999; Biondi et al., 2000) and DNA-dependent protein kinase (DNA-PK) (Feng et Dong and Liu, 2005) . Biochemically distinct properties argue against PDK1 and ILK1 in favor of a separate molecular identity of HM kinase activity (Hill et al., 2002; Hodgkinson et al., 2002) . In an elegant study from the Sabatini laboratory, mTOR complex-2 (mTORC2) was ultimately identified as this physiological PDK2 kinase activity (Sarbassov et al., 2005) , a finding which has since been repeated in other systems and is generally accepted in the field (for review, see Guertin and Sabatini, 2007; Reiling and Sabatini, 2006) . mTORC2 directly phosphorylates the HM site in vitro and enhances subsequent phosphorylation of Akt by PDK1 (Sarbassov et al., 2005) . In addition, mTORC2 is sensitive to PI3K inhibitors but insensitive to staurosporine, pharmacological properties that have been the gold standard for candidate PDK2 activities (for review, see Dong and Liu, 2005) . In further studies, siRNA knockdown of rictor, mTOR, mammalian LST8/G-protein b-subunit like protein (mLST8/GbL) and mammalian stress-activated protein kinase interacting protein 1 (mSIN1) as primary components of mTORC2 confirms its molecular identity: siRNA knockdown of any mTORC2 component inhibits phosphorylation of the HM site both after stimulation with insulin and in genetically modified mice (Frias et al., 2006; Guertin et al., 2006) .
All of these results provide strong support for mTORC2 to be PDK2. Still, they do not preclude that other candidate kinases for PDK2 (or yet to be uncovered kinases) could have functions in Akt activation under certain conditions. Bozulic et al. (2008) have provided evidence that DNA-PK mediates Akt phosphorylation at the HM site after induction of DNA double-strand break ends. Similarly, the ability of ILK1 to function as a protein kinase is still controversial, as it has been noted that ILK1 is missing critical residues that are found to be essential for catalysing phosphotransfer reactions in other kinases (Lynch et al., 1999) . However, a possible answer to the conundrum surrounding the function of ILK1 in Akt regulation may be found in data from the Dedhar laboratory in which ILK1 was shown to interact with mTORC2 (McDonald et al., 2008) . Using pharmacological inhibitors and siRNAbased genetic manipulations, the authors of this study show that interaction between rictor and ILK1 is required for promoting Akt phosphorylation at the HM site.
The molecular mechanisms of Akt regulation are summarized in Figure 1 .
Genetic models of Akt signaling
In addition to genetic implications in human disease, the second argument in strong support of the biological relevance of the Akt signaling cascade arises from findings of its evolutionary conservation that extend to downstream components and their interdependence within the signaling pathway. Structural homologs of Akt kinases have been identified in all vertebrate and invertebrate species examined to date and include Akt-related kinases in Drosophila melanogaster, Caenorhabditis elegans and Dictyostelium discoides (Franke et al., 1994; Paradis and Ruvkun, 1998; Meili et al., 1999) . Genetic findings in D. melanogaster suggest a dual function for Akt depending on the developmental stage. In early embryos, loss of Akt activity after overexpression of dominant-negative PI3K or PTEN results in ectopic apoptosis (Scanga et al., 2000) , and experiments using genetic mutants suggest a conserved function for Akt in apoptosis regulation and tumorigenesis (Staveley et al., 1998) . At later developmental stages, the pathway primarily regulates cell size and does not affect apoptosis (Staveley et al., 1998; Verdu et al., 1999) .
In C. elegans, genetic complementation groups have significantly contributed to the analysis and understanding of the Akt signal transduction pathway. A comparison of the Akt signaling pathways in C. elegans and mammals indicates strong evolutionary conservation of the pathway (Paradis and Ruvkun, 1998) . Upstream regulators of akt-1 and akt-2 in C. elegans are close homologs of their mammalian counterparts. They include genes such as: DAF-18, a gene encoding a structural homolog of PTEN; age-1, a gene encoding a PI3K homolog; pdk-1, a gene encoding a PDK1 homolog; and other upstream components encoded by the insulin-like (ins-1) and insulin/IGF1 receptor (daf-2) genes (Ogg and Ruvkun, 1998; Paradis et al., 1999; Pierce et al., 2001 ). These findings, by complementing experimental evidence in mammalian cells, underscore a pivotal and conserved function of Akt.
Mouse models of altered Akt function
Selective disruption of Akt genes in the mouse germ line results in isoform-deficient mice with specific phenotypes: Akt1 (À/À) mice show placental hypotrophy, accompanied by retardation of growth and reduction of body weight (Chen et al., 2001; Cho et al., 2001b) ; Akt2 (À/À) mice become hyperinsulemic and hyperglycemic (Cho et al., 2001a) ; and Akt3 (À/À) mice exhibit reduced brain sizes (Easton et al., 2005; Tschopp et al., 2005) . The absence of full functional compensation, according to which not all Akt isoforms perform equally, is also suggested by studies in mouse embryonic fibroblasts from different strains of Akt-deficient mice, in which the lack of specific Akt isoforms exerts distinct cellular phenotypes (Yun et al., 2008) . Still, the fact that all singular isoform knockout mutants are viable with only subtle differences in phenotype indicates the capacity of the three Akt isoforms to compensate for each other. In support of this idea, the phenotype of Akt1/Akt2 double-null mice shows severe dwarfism, atrophy of multiple organ systems including skin and skeletal muscle, failed adipogenesis and results in early neonatal lethality (Peng et al., 2003) . In spite of all the enumerated defects, Akt1/Akt2 double-null mice develop normally during embryogenesis and no significant apoptosis is observed. Akt2/Akt3 double-null mice are viable but display impaired glucose homeostasis and growth deficiencies (Dummler et al., 2006) . Future studies will determine which mechanisms compensate for the loss of Akt function. Candidate kinases to substitute for Akt function exist: kinases regulate similar substrates [such as serum-and glucocorticoid-induced protein kinase (SGK)] (Brunet et al., 2001) ; others are even activated by similar factors [such as cytokineindependent survival kinase (CISK)/SGK3] (Liu et al., 2000) .
Transgenic studies have expressed mutant Akt from tissue-specific promoter systems. Studies using activated Akt1 in T-cells have found increased apoptosis resistance, tumor formation and increased autoimmunity in aged transgenic animals (Jones et al., 2000; Malstrom et al., 2001) . Studies using overexpression of activated Akt1 in mouse mammary glands or neural progenitor cells have observed increased tumor formation, but only when Akt1-transgenic animals were crossed with animals carrying activated alleles of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras) or mutated middle T oncoprotein (Holland et al., 2000; Hutchinson et al., 2001) . In the mammary model, apoptosis during the involution of the mammary gland after weaning of pups was suppressed (Hutchinson et al., 2001) . Other groups have studied the importance of Akt in ovarian Figure 1 Canonical schematic depicting the present state of our understanding of Akt activation and regulation of downstream biological responses. Autophosphorylation of RTKs induces the recruitment of p85 regulatory subunits leading to PI3K activation. Once activated, p110 catalytic subunits phosphorylate plasma membrane-bound phosphoinositides (PI-4-P and PI-4,5-P 2 ) on the D3-position of their inositol rings. The second messengers resulting from this PI3K-dependent reaction are PI-3,4-P 2 and PI-3,4,5-P 3 (also called PIP 3 ). PIP 3 , in turn, is the substrate for the phosphoinositide 3-phosphatase PTEN, an endogenous inhibitor of PI3K signaling in cells. The phosphoinositide products of PI3K form high-affinity binding sites for the PH domains of intracellular molecules. PDK1 and Akt are two of the many targets of PI3K products in cells. Following binding of the Akt PH domain to PI3K products, Akt is phosphorylated by PDK1 on a critical threonine residue in its kinase domain. mTORC2 is the main kinase activity that through phosphorylation of a C-terminal HM serine residue locks Akt enzyme into an active conformation. Other kinases such as DNA-PK and ILK1 are also capable of phosphorylating Akt at the HM site but may do so in a cell-or context-dependent manner. Akt activation is blunted by phosphatases including PP2A and PHLPP that inhibit Akt activity by dephosphorylation. Studies examining Akt-interacting proteins such as CTMP or second messengers such as Ins(1,3,4,5)P 4 suggest that this common pathway of Akt regulation may be further specified within certain functional contexts or during development. Once activated, Akt activation is channeled into a plethora of downstream biological responses reaching from angiogenesis, cell survival, proliferation, translation to metabolism.
Akt signaling in animal physiology and human disease TF Franke tumor models (Orsulic et al., 2002) . Prostate-restricted activation of Akt in mice is sufficient to induce cell proliferation (prostatic intraepithelial neoplasia) and results in phenotypic changes (bladder obstruction) (Majumder et al., 2003) . Taken together, data from genetic models suggest that Akt1 expression by itself does not promote oncogenic transformation, even in systems where PI3K overexpression causes transformation (Aoki et al., 1998; Zhao et al., 2003) . Instead, cell size is found to be frequently increased.
Interacting proteins that regulate Akt activity and substrate specificity
The findings of nonredundancy in Akt isoforms suggest additional mechanisms that fine-tune the participation of Akt in its diverse biological functions. Mainly by using yeast two-hybrid screens, numerous proteins have been identified that interact with one or more domains of Akt and one or more of its isoforms (for review, see Brazil et al., 2002; Du and Tsichlis, 2005; Franke, 2008) . Akt-interaction proteins include several enzymes: PDK1 (Balendran et al., 1999) , inosine-5 0 monophosphate dehydrogenase (Ingley and Hemmings, 2000) , histone H3 methyltransferase SETDB1 , Src (Jiang and Qiu, 2003) and both known isoforms of the PH domain leucine-rich repeat protein phosphatase family (PHLPP) (Gao et al., 2005; Brognard et al., 2007) . Other Akt-interacting proteins lack discernible intrinsic enzymatic activity. This shared property suggests that their interaction with Akt isoforms affects enzymatic activity, access to upstream regulatory components, or intracellular localization and distribution. Thus, consequences of binding for Akt function are diverse and may differ depending on cell types and experimental conditions (for review, see Franke, 2007) .
Akt-interacting proteins bind to different functional domains. PH domain-interacting proteins include the Tcl1 oncogene and its related family members (for review, see Noguchi et al., 2007) , Ras GTPase-activating protein (RasGAP) (Yue et al., 2004) , c-Jun N-terminal kinase (JNK) interacting protein 1 (JIP1) (Kim et al., , 2003 , growth factor receptor-binding protein-10 (Grb10) (Jahn et al., 2002) , casein kinase 2-interacting protein-1 (Tokuda et al., 2007) and Ca 2 þ /calmodulin (Dong et al., 2007) . Heat shock protein 90 (HSP90) (Basso et al., 2002) , tribbles homolog 3 (TRB3) (Du et al., 2003) , adaptor protein containing PH domain, PTB domain and leucine zipper motif (APPL) (Mitsuuchi et al., 1999) and the BTB/POZ domaincontaining protein BTBD10 (Nawa et al., 2008) interact with its kinase domain. Examples of proteins interacting with its C-terminus include C-terminal modulator protein (CTMP) (Maira et al., 2001) , Akt phosphorylation enhancer (APE) (Anai et al., 2005) , Arg-binding protein 2 (ArgBP2)-g (Yuan et al., 2005) and prohibitin 2 . The JNK adaptor Plenty of SH3s (POSH) binds to both the N-and C-terminus of Akt (Figueroa et al., 2003) . Finally, for other Akt-interacting partners such as keratin-10 ( Paramio et al., 2001) , the binding sites on Akt have yet to be characterized.
Thus far, the importance of Akt binding proteins was mainly defined under pathological conditions. For example, overexpression of Tcl-1 in human T-cell prolymphocytic leukemia contributes to pathogenesis by facilitating Akt activation and altering its intracellular localization (for review, see Noguchi et al., 2007) . However, it is an attractive idea that interactors of Akt indeed may guide Akt activity and specificity under physiological conditions. In support of the physiological importance of endogenous competitors for PI3K second messenger binding to the Akt PH domain, Jia et al. (2007) have demonstrated that inositol 1,3,4,5-tetrakisphosphate [Ins(1,3,4,5)P 4 ] is a specific functional inhibitor of PI3K-dependent signaling in neutrophils. In this paradigm, Ins(1,3,4,5)P 4 is generated as a result of Ins(1,4,5)P3 kinase activation after chemoattractant stimulation and competes for binding to PI3K products, thus blocking Akt activation. In addition, a study from the Molling laboratory has shown that expression of the Akt-interacting protein WD-repeat propeller-FYVE (ProF) is upregulated during adipocyte differentiation, at which point it increases interaction of Akt with the forkhead-related transcription factor FoxO1 (Fritzius and Moelling, 2008) . Similarly, Hao et al. (2008) have provided evidence that JIP1 can act as a functional bridge between Akt and the guanine nucleotide exchange factor RalGDS, which in turn may determine the signal strength of PDK1 toward Akt downstream of Ras. And finally, at least in zebrafish, members of the APPL protein family modulate signaling specificity of the signal network downstream of Akt during development (Schenck et al., 2008) . In these experiments, depletion of Appl1 by morpholino knockdown in zebrafish selectively decreases the phosphorylation of glycogen synthase kinase 3 (GSK3)-b but not tuberous sclerosis protein-2 (TSC2).
Substrate phosphorylation by Akt
Consequences of Akt activation include diverse biological responses, ranging from primarily metabolic functions such as glucose transport, glycolysis, glycogen synthesis and the suppression of gluconeogenesis to protein synthesis, increased cell size, cell-cycle progression and apoptosis suppression.
Insights into the molecular consequences of increased Akt activation were derived from seminal studies that ultimately identified the 'orphan' proto-oncogene as an obligate intermediate downstream of PI3K in the insulin-dependent metabolic control of glycogen synthesis. When searching for kinases that could regulate GSK3, the groups of Brian Hemmings and Phil Cohen realized that Akt inhibited GSK3 activity in an insulinstimulated and PI3K-dependent manner by direct phosphorylation of an N-terminal regulatory serine residue (Cross et al., 1995) . By systematically permutating the amino-acid sequence surrounding the Akt phosphorylation site in GSK3, Alessi et al. (1996b) derived an optimal peptide sequence for Akt phosphorylation (R-X-R-X-X-S/T; where R is an arginine residue, S is serine, T is threonine and X is any amino acid). This Akt consensus motif is a common feature of known substrates of Akt, and its presence predicts reasonably well whether a given protein may be phosphorylated by Akt enzyme in vitro (for review, see Manning and Cantley, 2007) . Experiments using randomized permutations on the basis of the motif to optimize substrate peptides have defined the requirement for optimal phosphorylation by Akt further (Obata et al., 2000) . The preferred phosphoacceptor for Akt-dependent phosphorylation is a serine residue, but a synthetic substrate peptide with a threonine residue as the phosphoacceptor instead (R-P-R-A-A-T-F; P ¼ proline, A ¼ alanine, F ¼ phenylalanine) is also easily phosphorylated. For achieving optimal phosphorylation efficiency, the phosphoacceptor is best followed by a hydrophobic residue with a large side-chain in the p þ 1 position, and preceded by a serine or threonine at the pÀ2 position.
Targets of Akt with implications in apoptosis suppression
One of the first targets of Akt to be identified that has direct implications for regulating cell survival is the proapoptotic BCL2-antagonist of death (BAD) protein. BAD regulation by Akt has exemplified the molecular pathways linking survival factor signaling to apoptosis suppression (for review, see . When BAD is not phosphorylated, it will inhibit Bcl-x L and other anti-apoptotic Bcl-2 family members by direct binding of its Bcl-2 homology domain to their hydrophobic grooves (Gajewski and Thompson, 1996) . Once phosphorylated, these phospho-serine residues of BAD form high-affinity binding sites for cytoplasmic 14-3-3 molecules. As a result, phosphorylated BAD is retained in the cytosol where its pro-apoptotic activity is effectively neutralized (Zha et al., 1996) . The importance of BAD as an integration point of survival signaling is underscored by the fact that it is a substrate for multiple independent kinase pathways in cells, not all of which phosphorylate BAD at the same site(s) as Akt (Datta et al., 2000) . The mechanisms of 14-3-3-dependent regulation of BAD function hereby resemble the Aktdependent inhibition of FoxO transcription factors that regulate the transcription of pro-apoptotic genes (Brunet et al., 1999) .
The function of Akt extends beyond maintaining mitochondrial integrity to keep cytochrome c and other apoptogenic factors in the mitochondria (Kennedy et al., 1999) . Akt activity also mitigates the response of cells to the release of cytochrome c into the cytoplasm. Although caspase-9 is an Akt substrate in human cells, where it may explain cytochrome c resistance (Cardone et al., 1998) , it may not be the only, or even the most important, target because Akt-dependent cytochrome c resistance can be observed in animal species where caspase-9 lacks a potential Akt phosphorylation site (Fujita et al., 1999; Zhou et al., 2000) . Not surprisingly, other components of the post-mitochondrial machinery such as the X-linked inhibitor of apoptotic proteins (XIAP) have been suggested as potential Akt substrates (Dan et al., 2004) .
Akt-dependent inhibition of stress-regulated kinase cascades
Another important class of Akt targets are proteins involved in the stress-activated/mitogen activated protein kinase (SAPK/MAPK) cascades. Growing experimental evidence points to a close functional relationship between the Akt survival pathway and SAPK/MAPK cascades that are activated by various cellular stresses and are linked to apoptosis. Increased Akt activity has been shown to suppress the JNK and p38 pathways (Berra et al., 1998; Cerezo et al., 1998; Okubo et al., 1998) . It has been shown that apoptosis signal-regulating kinase 1 (ASK1) is regulated by Akt and contains an Akt-specific phosphorylation site (Kim et al., 2001 ). These findings have been confirmed independently by other groups (Yuan et al., 2003; Mabuchi et al., 2004) . Thus, ASK1 is likely to be one of the points of convergence between PI3K/Akt signaling and stressactivated kinase cascades, although probably not the only one. Akt also phosphorylates the small G protein Rac1 (Kwon et al., 2000) , the MAP2K stress-activated protein kinase kinase-1 (SEK1; also known as JNKK1 or MKK4) and the MAP3K mixed lineage kinase 3 (MLK3) (Barthwal et al., 2003; Figueroa et al., 2003) . Using yeast-2-hybrid screens to identify interacting partners for Akt kinases, Figueroa et al. (2003) found binding of Akt2 to the JNK adaptor POSH. These authors showed that the binding of Akt2 to POSH results in an inhibition of JNK activity, and that this inhibition is mediated by phosphorylation of the upstream kinase MLK3 and leads to the disassembly of the JNK signaling complex. In turn, POSH is also an Akt substrate (Lyons et al., 2007) . Taken together, these findings point to an intriguing model for the regulation of the JNK pathway by Akt, in which the Aktdependent phosphorylation of specific components can block signal transduction through the stress-regulated kinase cascade. In spite of this, it has been reported that Akt also blocks the pro-apoptotic activity of other MAP3Ks such as MLK1 and MLK2 that act in parallel to MLK3 but do not contain a typical Akt consensus phosphorylation motif . Thus, phosphorylation-based mechanisms may be limited in explaining the role of Akt in blocking JNK signaling.
Akt substrates with metabolic functions
Several Akt-dependent mechanisms mediate the regulation of insulin-dependent glucose homeostasis downstream of PI3K. These include the insulin-mediated increase in glycogen synthesis and suppression of glycogenolysis through the Akt-dependent phosphorylation and inactivation of GSK3. Nonphosphorylated GSK3 is catalytically active and inhibits the activity of glycogen synthase, which is the rate-limiting enzyme in glycogen synthesis through a phosphorylation-dependent mechanism (Cross et al., 1995) . In the liver, suppression of hepatic glucose production and glycogenolysis is further enhanced by the insulin-mimicking peripheral effects of leptin. Leptin induces Akt activity in vitro and in vivo in pathways parallel to those utilized in insulin signaling Szanto and Kahn, 2000) . It antagonizes the increase of cAMP levels by glucagon, presumably by inducing the Akt-dependent phosphorylation of phosphodiesterase 3B (Zhao et al., 2000) .
Other metabolic effects of Akt activation include the phosphorylation and activation of 6-phosphofructo-2-kinase (Deprez et al., 1997) . In addition, Akt activation has been shown to cause the translocation of hexokinase to the mitochondria for the purpose of eliciting the capture of intracellular glucose by phosphorylation . Furthermore, Akt has been implicated in increased lipogenesis through the phosphorylation of ATP-citrate lyase (Berwick et al., 2002) . Finally, in addition to modifying glucose metabolism, Akt activity increases the transcription of the glucose transporters GLUT1 (Barthel et al., 1999) and the translocation of GLUT4 to the plasma membrane in muscle and fat cells (Kohn et al., 1996) , thus increasing the uptake of glucose into cells. Other substrates of Akt with a possible involvement in metabolic regulation include Akt substrate of 160 kDa (AS160), which may mediate the regulation of GLUT4 translocation by Akt (Sano et al., 2003) , phosphoinositide kinase for five position containing a Fyve finger (PIKfyve) (Berwick et al., 2004) and syntaxin binding protein 4 (STXBP4/ synip) (Yamada et al., 2005) .
Although many of its substrates are involved in clearly defined biological functions within a circumscribed context such as cell proliferation, a more thorough analysis of Akt signaling has suggested that the boundaries between metabolic processes and apoptosis suppression may be artificial. For example, the Akt target GSK3 has been implicated both in the regulation of glucose metabolism and cell survival (Pap and Cooper, 1998) . These findings suggest that the distinctions between cell growth, survival, metabolism and apoptosis regulation do not properly reflect functional interactions between concurrent biological processes in cells. This shift in perception has been fueled by studies from the Korsmeyer laboratory that have demonstrated a canonical function for the pro-apoptotic Bcl-2 family member BAD in the regulation of glucokinase activity (Danial et al., 2003) . It is conceivable that findings of PKA-dependent regulation of BAD in glucose metabolism can be extrapolated to BAD inhibition by Akt. Still, a formal confirmation for a role of Akt in this process has yet to be presented (for review, see Downward, 2003) .
Overall, the efforts in attributing metabolic functions with implications for cell viability to Akt have been limited, as many of the subtle effects of Akt on cellular homeostasis may be difficult to detect Plas et al., 2001) . Still, these functions of Akt may be of fundamental relevance for the maintenance of the cellular machinery, the production and availability of nutrients, and also other building blocks needed for basic cellular functions (for review, see Plas et al., 2002) .
Mechanisms of Akt-dependent cell-cycle regulation
The regulation of the cell cycle by Akt is well established. Akt activity affects at least two key cellcycle regulator proteins: p21
Cip1/WAF1 and p27
Kip1
. p21
Cip1/WAF1 is stabilized after activation of the Akt pathway by direct phosphorylation and also after Aktdependent inhibition of GSK3 (Rossig et al., 2001 (Rossig et al., , 2002 Li et al., 2002) . Furthermore, Zhou et al. (2001) showed that the phosphorylation of p21
Cip1/WAF1 by Akt inhibits its interaction with proliferating cell nuclear antigen (PCNA) and promotes the assembly of the cyclin D1:cyclin-dependent kinase 4 (CDK4) complex. Akt also phosphorylates p27 Kip1 , which in turn is a target gene of FoxO transcription factors. Phosphorylation of p27
Kip1 induces cytoplasmic localization and inhibition, similar to the regulation of p21
Cip1/WAF1 (Liang et al., 2002; Shin et al., 2002) .
Additional evidence for the involvement of Akt in the regulation of cell proliferation is found at the interface between p53 tumor suppressor signaling and Akt activity. Akt phosphorylates the ubiquitin ligase mouse double minute homolog 2 (Mdm2) and its human homolog HDM2 that are induced by p53 and block p53 function. Two proposed mechanisms of Aktdependent regulation of Mdm2 include the Akt-dependent increase of Mdm2's nuclear import (Mayo and Donner, 2001 ) and its intrinsic ubiquitin ligase activity (Zhou et al., 2001; Ashcroft et al., 2002; Ogawara et al., 2002) . There is also cross talk between PTEN and p53. PTEN not only regulates p53 protein levels through Akt and Mdm2, but also directly interacts with p53 and enhances its transcriptional activity (Freeman et al., 2003) . Conversely, on the basis of the finding of a p53 binding site within the PTEN promoter, Stambolic et al. (2001) have presented evidence for the regulation of PTEN transcription by p53.
mTOR and Akt: increasing cell size matters
Although Akt promotes cell proliferation by regulating specific targets related to the cell cycle machinery and to DNA damage-dependent cell responses, a conserved function of PI3K/Akt signal transduction is found in regulating cell volume (for review, see Franke et al., 2003) . For example, expression of constitutively active mutants or dominant-negative mutants specifically in cardiomyocytes of transgenic mice results in enlarged or reduced heart sizes, respectively (Shioi et al., 2000 (Shioi et al., , 2002 . Conversely, cell volumes are decreased in Akt1 and Akt3 knockout mice (Cho et al., 2001b; Easton et al., 2005) .
The main effector of Akt in the context of cell growth pathway is the product of the tuberous sclerosis (TSC) gene TSC2. Reduced TSC2 (also called tuberin) together with loss of TSC1 (also known as hamartin) is frequently found in TSC, an autosomal dominant tumor disease affecting 1 in 6000 individuals. TSC2 phosphorylation by Akt induces the activity of mTORC1 by relieving Ras enriched in brain (Rheb) GTPase from the inhibition of the TSC1/TSC2 complex (Tee et al., 2003) . A second binding partner of mTOR and also a substrate for Akt is proline-rich Akt substrate 40 kDa (PRAS40). Underphosphorylated PRAS40 binds raptor and inhibits mTOR kinase activity (Sancak et al., 2007; Wang et al., 2007) . As a result, ribosomal protein kinase p70S6k and eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) are phosphorylated by mTOR (Inoki et al., 2002; Tee et al., 2002) , thus leading to increased translation of existing mRNA transcripts (for review, see Mamane et al., 2006) .
The dual involvement of mTOR in mTORC1 as an effector downstream of Akt and also as an upstream regulatory kinase when in mTORC2 suggests the evolution of a tightly regulated feedback loop to coordinate growth and nutrient utilization. In addition to regulating Akt phosphorylation, mTOR attenuates PI3K activity by phosphorylation of the insulin-receptor substrate IRS1 (for review, see Harrington et al., 2005; Manning, 2004) . This may explain in part why TSC is characterized by an increase in cell size but rarely leads to the kind of highly malignant tumors that are observed after PTEN loss of function (for review, see Cheadle et al., 2000) . Additional data showing that chronic treatment with rapamycin reduces Akt phosphorylation, presumably by soaking up mTOR in mTORC2, offer promising routes for therapeutic intervention in cancers caused by hyperactivation of Akt (Sarbassov et al., 2006; Zeng et al., 2007) . In spite of this, the observation that certain tumors respond to rapamycin with increased Akt signaling and a more aggressive phenotype (for review, see Easton et al., 2006) indicates the need to develop mTOR inhibitors that act on sites other than the rapamycin binding site (Sarbassov et al., 2006) .
Beyond cancer: PI3K/Akt signaling in higher brain function
The critical importance of Akt signaling for neuronal function is implied from several lines of in vitro evidence using neuronal cell lines and dispersed primary neuronal cultures that have demonstrated a requirement for Akt in the protection against trophic factor deprivation, oxidative stress and ischemic injury (Dudek et al., 1997; Salinas et al., 2001; Noshita et al., 2002) . Dysregulation of Akt activity is observed in neurodegenerative diseases including Alzheimer's disease (Rickle et al., 2004; Ryder et al., 2004 ), Parkinson's disease ) and Huntington's disease (Humbert et al., 2002) , and it is also associated with the pathobiological mechanisms underlying spinocerebellar ataxia . A mechanistic involvement of impaired Akt signaling in neurodegeneration is further supported by the Akt-dependent phosphorylation of the diseaserelated proteins huntingtin (Humbert et al., 2002) and ataxin .
Other studies suggest that the involvement of Akt in brain function extends beyond the protection of neuronal cells against apoptotic insults. Indeed, pathological changes in Akt signal transduction have been described that are associated with mental diseases. Significantly decreased Akt1 expression has been reported in patients suffering from familial schizophrenia (Emamian et al., 2004) . Decreased Akt1 levels are correlated with increased GSK3 activity, presumably because of the lack of the Akt-dependent inhibitory input on GSK3. In support of AKT1 being a susceptibility gene for schizophrenia, Akt1
(À/À) mice exhibit increased sensitivity to the sensorimotor disruptive effect of amphetamine, which is partly reversed by the treatment of mutant mice with the antipsychotic drug haloperidol (Emamian et al., 2004) . Additional support for a contribution of impaired Akt signaling in the pathogenesis of schizophrenia derives from the finding of mutant PI3K signaling in schizophrenia (for review, see Arnold et al., 2005) . A direct involvement of Akt in dopaminergic action is indicated by the observation that Akt1 (À/À) mutant mice exhibit a behavioral phenotype resembling enhanced dopaminergic transmitter function (Emamian et al., 2004) . By interacting with the GSK3 pathway, Akt modulates the suppression of dopamine (DA)-associated behaviors after treatment with the mood stabilizer lithium (Beaulieu et al., 2004) . Furthermore, a b-arrestin 2-mediated kinase/phosphatase scaffold of Akt and protein phosphatase A (PP2A) is required for the regulation of Akt downstream of DA receptors (Beaulieu et al., 2005) . Still, the role of Akt in dopaminergic responses by far exceeds actions downstream of DA receptors: the insulin-dependent regulation of DA transporter also depends on Akt activity (Garcia et al., 2005) .
Since the field of Akt signaling in psychiatric disorders is still emerging, it may be too early to speculate about the molecular involvement of Akt in regulating higher brain function. Possible functional outlets of Akt include some of the substrates mentioned above, including mTORC1 and GSK3. In addition, substrates of Akt related to synaptic plasticity and transmission have been described. One such novel substrate of Akt related to neuronal excitability is the b2-subunit of the type A g-aminobutyric acid receptor (GABA A -R) . In support of a direct involvement of Akt in synaptic function, studies directed at working memory performance performed in Akt1 (À/À) mice (Lai et al., 2006) and in healthy individuals carrying the AKT1 coding variation observed in familial schizophrenia (Tan et al., 2008) find a strong correlation with cognitive performance. Additional roles for Akt in higher brain function are suggested by studies from the Nestler laboratory that have explored the IRS2-Akt pathway during the development of tolerance to opiate reward (Russo et al., 2007) . By using viral-mediated gene transfer to express mutant Akt in midbrain neurons, these authors demonstrate that downregulation of the IRS2-Akt pathway mediates morphine-induced decreases in cell size of DA neurons in brain regions that are critically involved in the reward circuitry and affected in individuals addicted to drugs of abuse.
Finally, TSC patients show an increased incidence of autism spectrum disorders (ASD) ranging from 25 to 50% (for review, see Wiznitzer, 2004) . Individuals with macrocephaly due to Lhermitte-Duclos disease are prone to ASD and show a pronounced incidence of mutations in the PTEN tumor suppressor gene (Butler et al., 2005) . Additional experimental support for a possible involvement of PTEN/Akt in ASD is provided by data from the Parada laboratory examining the morphology and behavior of mutant mice with neuron-specific knockout of PTEN (Kwon et al., 2006) . Future studies will be required to clarify the function of Akt in cognition and characterize the underlying molecular mechanisms. In spite of this, these initial studies suggest a complex function of Akt in conditions affecting brain function and mental health.
The emerging involvement of Akt in higher brain function is summarized in Figure 2 .
Conclusions
When considering the present understanding of all the signals leading to and from Akt, we face a growing complexity that is in part compounded by the intersection of multiple signaling cascades. Many substrates of Akt are shared with other kinases that have similar specificities. Moreover, signals originating from activated Akt do not simply lead to changes in the biological activity of specific downstream substrates, but affect entire signaling networks. In spite of this, there is hope that there is order to the far-reaching physiological involvement of Akt. One possibility is that differential regulation of the binding partners of Akt may determine cell-and context-specific signaling by Akt. Studies are now needed to elucidate the Figure 1 , including activation of PI3K by RTKs including IGF-1/insulin and nerve growth factor (BDNF/NT-3) receptors. Other mechanisms governing Akt activity in neuronal cells include G-coupled receptors for the monoamine neurotransmitters serotonin (5-HT) (for review, see Raymond et al., 2001 ) and dopamine (DA) (for review, see Beaulieu et al., 2007) . Depending on receptor type (D 2 -DA and 5-HT 1A receptors vs D 1 -DA receptors), binding of 5-HT or DA decreases or increases the activity of adenylyl cyclase (AC), respectively. Changes in cAMP second messenger levels, in turn, alter PKA and PP2A activity. PP2A is inhibited by increased PKA activity, thus maintaining Akt in an activated state after 5-HT 1A receptor simulation (Hsiung et al., 2008) . After binding of DA to D 2 -DA receptor, following initial inhibition of AC, a secondary internalization complex is formed between b-arrestin 2, PP2A and Akt leading to the inhibition of Akt. In neuronal cells, activated Akt regulates diverse targets that have been implicated in the regulation of protein translation and cell size (mTORC1), axonal outgrowth (GSK3), apoptosis suppression (BAD) and synaptic plasticity (GABA A -R). Details regarding functional consequences of Akt regulation for higher brain function are discussed in the text. physiological functions of the binding partners of Akt in mammalian physiology.
A second challenge that the field is facing arises from the involvement of Akt in multiple areas of physiology. These now exceed cancer and diabetes and, as briefly outlined above, include higher brain functions related to cognition. This far-reaching involvement poses important questions to researchers trying to find inhibitors of Akt signaling in cancer therapy. Indeed, psychiatrists may want to boost Akt signaling in patients suffering from schizophrenia. Most likely, tissue-specific solutions can be applied. However, the plethora of Akt-dependent biological responses may also require new approaches in the scientific community when examining Akt. Thus, rather than examining the Akt pathway within a specific field, it may be necessary that researchers from different subject areas, but all interested in questions related to Akt, exchange their findings and ideas. Today, tens of thousands of papers on Akt have been published, with the rate of publications still increasing. To organize this information in a comprehensive manner and expand the field beyond the confines of specific research fields has become a difficult Akt to follow.
